This study aimed to characterize TET2 mutations in CN-AML, assess their clinical features, and evaluate the prognostic impact of VAF and clonal hierarchy on overall survival (OS) and relapse-free survival (RFS). This evidence concerns the gene TET2 and acute myeloid leukemia.